Episode Details
Back to Episodes
Pharmaceutical Executive Daily: Novo Nordisk Resubmits BLA for Awiqli
Published 7 months, 2 weeks ago
Description
In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s resubmission of its BLA for Awiqli, the FDA’s approval of Kedrion’s Qivigy for primary humoral immunodeficiency, and Eli Lilly’s decision to halt development of a muscle-preserving weight-loss therapy.